{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:22:43Z","timestamp":1760782963411},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Current Science Inc"],"published-print":{"date-parts":[[2007,3]]},"DOI":"10.1007\/s11906-007-0010-x","type":"journal-article","created":{"date-parts":[[2007,4,25]],"date-time":"2007-04-25T16:26:36Z","timestamp":1177518396000},"page":"53-58","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Therapeutic potential of blockade of the Urotensin II system in systemic hypertension"],"prefix":"10.1007","volume":"9","author":[{"given":"Henry","family":"Krum","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Will","family":"Kemp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,4,26]]},"reference":[{"key":"10_CR1","first-page":"533","volume":"41","author":"H. Bern","year":"1985","unstructured":"Bern H, Pearson D, Larson B, Nishioka R: Complete amino acid sequence of urotensin I, a hypotensive and corticotropin-releasing neuropeptide from Catostomus. Recent Prog Horm Res 1985, 41:533\u2013552.","journal-title":"Recent Prog Horm Res"},{"key":"10_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/sj.bjp.0704671","volume":"136","author":"N. Elshoubagy","year":"2002","unstructured":"Elshoubagy N, Douglas S, Shabon U, et al.: Molecular and pharmacological characteristics of genes encoding urotensin II peptides and their cognate G-protein-coupled receptors from the mouse and monkey. Br J Pharmacol 2002, 136:9\u201322.","journal-title":"Br J Pharmacol"},{"key":"10_CR3","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/S0014-5793(99)01003-0","volume":"457","author":"Y. Coulouarn","year":"1999","unstructured":"Coulouarn Y, Jegou S, Tostivint H, et al.: Cloning, sequence analysis and tissue distribution of the mouse and rat urotensin II precursors. FEBS Lett 1999, 457:28\u201332.","journal-title":"FEBS Lett"},{"key":"10_CR4","doi-asserted-by":"publisher","first-page":"5021","DOI":"10.1073\/pnas.77.8.5021","volume":"77","author":"D. Pearson","year":"1980","unstructured":"Pearson D, Shively J, Clark B, et al.: Urotensin II: a somatostatin-like peptide in the caudal neurosectretory system of fishes. Proc Natl Acad Sci U S A 1980, 77:5021\u20135024.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10_CR5","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1159\/000072742","volume":"3","author":"H. Krum","year":"2003","unstructured":"Krum H, Kompa A, Hannan R, Thomas W: Emerging role of the urotensin II system in cardiovascular disease. Heart Drug 2003, 3:153\u2013158.","journal-title":"Heart Drug"},{"key":"10_CR6","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1021\/jm0309912","volume":"47","author":"A. Carotenuto","year":"2004","unstructured":"Carotenuto A, Grieco P, Campiglia P, et al.: Unraveling the active confirmation of urotensin II. J Med Chem 2004, 47:1652\u20131661.","journal-title":"J Med Chem"},{"key":"10_CR7","first-page":"533","volume":"41","author":"H. Bern","year":"1995","unstructured":"Bern H, Pearson D, Larson B, Nishioka R: Neurohormones from fish tails: the caudal neurosecretory system. I. \u201cUrophysiology\u201d and the caudal neurosecretory system of fishes. Recent Prog Hormone Res 1995, 41:533\u2013552.","journal-title":"Recent Prog Hormone Res"},{"key":"10_CR8","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.tips.2003.12.005","volume":"25","author":"S. Douglas","year":"2004","unstructured":"Douglas S, Dhanak D, Johns D: From \u2018gills to pills\u2019: urotensin-II as a regulator of mammalian cardiorenal function. Trends Pharmacol Sci 2004, 25:76\u201385.","journal-title":"Trends Pharmacol Sci"},{"key":"10_CR9","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1021\/jm0111043","volume":"45","author":"S. Flohr","year":"2002","unstructured":"Flohr S, Kurtz M, Kostenis E, et al.: Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance studies on urotensin II. J Med Chem 2002, 45:1799\u20131805.","journal-title":"J Med Chem"},{"key":"10_CR10","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1038\/sj.bjp.0702238","volume":"125","author":"S. Wilson","year":"1998","unstructured":"Wilson S, Bergsma D, Chambers J, et al.: Orphan G-protein-coupled receptors: the next generation of drug targets?. Br J Pharmacol 1998, 125:1387\u20131392.","journal-title":"Br J Pharmacol"},{"key":"10_CR11","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1006\/bbrc.1999.1796","volume":"266","author":"Q. Liu","year":"1999","unstructured":"Liu Q, Pong SS, Zeng Z, et al.: Identification of urotensin II as the endogenous ligand for the orphan G-protein-coupled receptor GPR14. Biochem Biophys Res Commun 1999, 266:174\u2013178.","journal-title":"Biochem Biophys Res Commun"},{"key":"10_CR12","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/sj.bjp.0704924","volume":"137","author":"J. Maguire","year":"2002","unstructured":"Maguire J, Davenport A. Is urotensin II the new endothelin?. Br J Pharmacol 2002, 137:579\u2013588.","journal-title":"Br J Pharmacol"},{"key":"10_CR13","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1161\/hh1101.092034","volume":"88","author":"V. Sauzeau","year":"2001","unstructured":"Sauzeau V, Mellionnec E, Bertoglio J, et al.: Human urotensin II induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-Kinase. Circ Res 2001, 88:1102\u20131104.","journal-title":"Circ Res"},{"key":"10_CR14","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1006\/bbrc.1999.1640","volume":"265","author":"M. Mori","year":"1999","unstructured":"Mori M, Sugo T, Abe M, et al.: Urotensin II is the endogenous ligand of a G-protein-coupled orphan receptor, SENR (GPR14). Biochem Biophys Res Comm 1999, 265:123\u2013129.","journal-title":"Biochem Biophys Res Comm"},{"key":"10_CR15","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/S0140-6736(01)06002-0","volume":"358","author":"K. Totsune","year":"2001","unstructured":"Totsune K, Takahashi K, Arihara Z, et al.: Role of urotensin II in patients on dialysis. Lancet 2001, 358:810\u2013811.","journal-title":"Lancet"},{"key":"10_CR16","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/45809","volume":"401","author":"R.S. Ames","year":"1999","unstructured":"Ames RS, Sarau HM, Chambers JK, et al.: Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 1999, 401:282\u2013286.","journal-title":"Nature"},{"key":"10_CR17","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/sj.bjp.0705254","volume":"139","author":"D. Behm","year":"2003","unstructured":"Behm D, Harrison S, Ao Z, et al.: Deletion of the UT receptor gene results in the selective loss of urotensin II contractile activity in the aortae isolated from UT receptor knockout mice. Br J Pharmacol 2003, 139:464\u2013472.","journal-title":"Br J Pharmacol"},{"key":"10_CR18","doi-asserted-by":"crossref","first-page":"H925","DOI":"10.1152\/ajpheart.2001.280.2.H925","volume":"280","author":"A. Stirrat","year":"2001","unstructured":"Stirrat A, Gallagher M, Douglas S, et al.: Potent vasodilatory responses to human urotensin II in human pulmonary and abdominal resistance arteries. Am J Physiol Heart Circ Physiol 2001, 280:H925\u2013H928.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10_CR19","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1161\/01.CIR.103.10.1378","volume":"103","author":"C. Hillier","year":"2001","unstructured":"Hillier C, Berry C, Petrie M, et al.: Effects of urotensin II in human arteries and veins of varying calibre. Circulation 2001, 103:1378\u20131381.","journal-title":"Circulation"},{"key":"10_CR20","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/sj.bjp.0703601","volume":"131","author":"J. Maguire","year":"2000","unstructured":"Maguire J, Kuc R, Davenport A: Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasconstrictor responses with endothelin-1. Br J Pharmacol 2000, 131:441\u2013446.","journal-title":"Br J Pharmacol"},{"key":"10_CR21","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/sj.bjp.0703811","volume":"132","author":"F. Russell","year":"2001","unstructured":"Russell F, Molenaar P, O\u2019Brien D: Cardiostimulant effects of urotenin II in human heart in vitro. Br J Pharmacol 2001, 132:5\u20139.","journal-title":"Br J Pharmacol"},{"key":"10_CR22","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1038\/sj.bjp.0703690","volume":"131","author":"S. Douglas","year":"2000","unstructured":"Douglas S, Sulpizio A, Piercy V, et al.: Differential vasoconstrictor activity of human urotensin II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br J Pharmacol 2000, 131:1262\u20131274.","journal-title":"Br J Pharmacol"},{"key":"10_CR23","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1038\/sj.bjp.0704051","volume":"132","author":"S. Gardiner","year":"2001","unstructured":"Gardiner S, March J, Kemp P, et al.: Depressor and regionally selective vasodilator effects of human and rat urotensin II in conscious rats. Br J Pharmacol 2001, 132:1625\u20131629.","journal-title":"Br J Pharmacol"},{"key":"10_CR24","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1097\/00004872-200301000-00026","volume":"21","author":"Y. Lin","year":"2003","unstructured":"Lin Y, Tsuchihashi T, Matsumura K, et al.: Central cardiovascular action of urotensin II in conscious rats. J Hypertens 2003, 21:159\u2013165.","journal-title":"J Hypertens"},{"key":"10_CR25","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S0008-6363(01)00485-0","volume":"53","author":"I. Wilkinson","year":"2002","unstructured":"Wilkinson I, Affolter J, de Haas S, et al.: High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in man. Cardiovasc Res 2002, 53:341\u2013347.","journal-title":"Cardiovasc Res"},{"key":"10_CR26","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1046\/j.1365-2125.2002.t01-1-01704.x","volume":"54","author":"J. Affolter","year":"2002","unstructured":"Affolter J, Newby D, Wilkinson I, et al.: No effect on central or peripheral blood pressure or systemic urotensin II infusion in humans. Br J Clin Pharmacol 2002, 54:617\u2013621.","journal-title":"Br J Clin Pharmacol"},{"key":"10_CR27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/sj.bjp.0704448","volume":"135","author":"F. Bohm","year":"2002","unstructured":"Bohm F, Pernow J: Urotensin II evokes potent vasoconstriction in humans in vivo. Br J Pharmacol 2002, 135:25\u201327.","journal-title":"Br J Pharmacol"},{"key":"10_CR28","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S1471-4892(03)00012-2","volume":"3","author":"S. Douglas","year":"2003","unstructured":"Douglas S: Human urotensin II as a novel cardiovascular target: \u2018heart\u2019 of the matter or simply a fishy \u2018tail\u2019?. Curr Opin Pharmacol 2003, 3:159\u2013167.","journal-title":"Curr Opin Pharmacol"},{"key":"10_CR29","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1161\/01.CIR.0000121326.69153.98","volume":"109","author":"M. Lim","year":"2004","unstructured":"Lim M, Honisett S, Sparkes C, et al.: Differential effect of urotensin II on vascular tone in normal subjects and patients with chronic heart failure. Circulation 2004, 109:1212\u20131214.","journal-title":"Circulation"},{"key":"10_CR30","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S0024-3205(02)01743-5","volume":"71","author":"A. Abdelrahman","year":"2002","unstructured":"Abdelrahman A, Pang C: Involvement of the nitric oxide\/L-arginine and sympathetic nervous systems on the vasodepressor action of human urotensin II in anesthetized rats. Life Sci 2002, 71:819\u2013825.","journal-title":"Life Sci"},{"key":"10_CR31","doi-asserted-by":"crossref","first-page":"F792","DOI":"10.1152\/ajprenal.00342.2002","volume":"285","author":"A. Zhang","year":"2003","unstructured":"Zhang A, Chen Y, Zhang D, et al.: Urotensin II is a nitric oxide-dependent vasodilator and natriuretic peptide in the rat kidney. Am J Physiol Renal Physiol 2003, 285:F792\u2013F798.","journal-title":"Am J Physiol Renal Physiol"},{"key":"10_CR32","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1097\/01.hjh.0000125452.28861.f1","volume":"22","author":"B. Cheung","year":"2004","unstructured":"Cheung B, Leung R, Bun Man Y, Wong L: Plasma concentration of urotensin II is raised in hypertension. J Hypertens 2004, 22:1341\u20131344.","journal-title":"J Hypertens"},{"key":"10_CR33","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1097\/00004872-200112000-00011","volume":"19","author":"M. Matsushita","year":"2001","unstructured":"Matsushita M, Shichiri M, Imai T, et al.: Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissue. J Hypertens 2001, 19:2185\u20132190.","journal-title":"J Hypertens"},{"key":"10_CR34","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/j.amjhyper.2005.03.748","volume":"18","author":"B. Sondermeijer","year":"2005","unstructured":"Sondermeijer B, Kompa A, Komesaroff P, Krum H: Effect of exogenous urotensin-II on vascular tone in skin micro-circulation of patients with essential hypertension. Am J Hypertens 2005, 18:1195\u20131199.","journal-title":"Am J Hypertens"},{"key":"10_CR35","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1097\/00004872-200112000-00012","volume":"19","author":"T. Watanabe","year":"2001","unstructured":"Watanabe T, Pakala R, Katagiri T, Benedict C: Synergistc effect of urotensin II with serotonin on vascular smooth muscle cell proliferation. J Hypertens 2001, 19:2191\u20132196.","journal-title":"J Hypertens"},{"key":"10_CR36","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1007\/s00210-004-0876-y","volume":"369","author":"F. Russell","year":"2004","unstructured":"Russell F, Molenaar P: Cardiovascular actions of human urotensin II\u2014considerations for hypertension. Naunyn Schmiedebergs Arch Pharmacol 2004, 369:274\u2013280.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10_CR37","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/S0140-6736(01)06002-0","volume":"358","author":"K. Totsune","year":"2001","unstructured":"Totsune K, Takahashi K, Arihara Z, et al.: Role of urotensin II in patients on dialysis. Lancet 2001, 358:810\u2013811.","journal-title":"Lancet"},{"key":"10_CR38","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1053\/j.ajkd.2004.07.021","volume":"44","author":"R. Langham","year":"2004","unstructured":"Langham R, Kelly DJ, Gow RM, et al.: Increased expression of urotensin II and urotensin receptor in human diabetic nephropathy. Am J Kidney Dis 2004, 44:826\u2013831.","journal-title":"Am J Kidney Dis"},{"key":"10_CR39","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1161\/01.RES.0000084382.64418.BC","volume":"93","author":"A. Tzanidis","year":"2003","unstructured":"Tzanidis A, Hannan RD, Thomas WG, et al.: Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy. Circ Res 2003, 93:246\u2013253.","journal-title":"Circ Res"},{"key":"10_CR40","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1161\/01.CIR.0000044388.19119.02","volume":"106","author":"L. Ng","year":"2002","unstructured":"Ng L, Loke I, O\u2019Brien R, et al.: Plasma urotensin in human systolic heart failure. Circulation 2002, 106:2877\u20132880.","journal-title":"Circulation"},{"key":"10_CR41","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S0140-6736(02)09709-X","volume":"360","author":"A. Richards","year":"2002","unstructured":"Richards A, Nicholls M, Lainchbury J, et al.: Plasma urotensin II in heart failure. Lancet 2002, 360:545\u2013546.","journal-title":"Lancet"},{"key":"10_CR42","doi-asserted-by":"crossref","first-page":"H1576","DOI":"10.1152\/ajpheart.00217.2003","volume":"285","author":"F. Russell","year":"2003","unstructured":"Russell F, Meyers D, Galbraith A, et al.: Elevated plasma levels of human urotensin II immunoreactivity in congestive heart failure. Am J Physiol Heart Circ Physiol 2003, 285:H1576\u2013H1581.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10_CR43","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1016\/S0140-6736(02)08831-1","volume":"359","author":"S. Douglas","year":"2002","unstructured":"Douglas S, Tayara L, Ohlstein E, et al.: Congestive heart failure and expression of myocardial urotensin II. Lancet 2002, 359:1990\u20131997.","journal-title":"Lancet"},{"key":"10_CR44","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/sj.bjp.0704887","volume":"137","author":"D. Behm","year":"2002","unstructured":"Behm D, Herold C, Ohlstein E, et al.: Pharmacological characterisation of SB-7104011 (Cpa-c\/D-Cys-Pal-D-Trp-Lys-Val-Cys]-Cpa-amide), a novel peptidic urotensin II receptor antagonist. Br J Pharmacol 2002, 137:449\u2013458.","journal-title":"Br J Pharmacol"},{"key":"10_CR45","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/sj.bjp.0704895","volume":"137","author":"V. Camarda","year":"2002","unstructured":"Camarda V, Guerrini R, Kostenis E, et al.: A new ligand for the urotensin II receptor. Br J Pharmacol 2002, 137:311\u2013314.","journal-title":"Br J Pharmacol"},{"key":"10_CR46","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/sj.bjp.0705251","volume":"139","author":"C. Herold","year":"2003","unstructured":"Herold C, Behm D, Buckles P, et al.: The neuromedin B receptor antagonist BIM-23127 is a potent antagonist at human and rat urotensin II receptors. Br J Pharmacol 2003, 139:203\u2013207.","journal-title":"Br J Pharmacol"},{"key":"10_CR47","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1124\/jpet.104.068320","volume":"311","author":"M. Clozel","year":"2004","unstructured":"Clozel M, Binkert C, Birker-Robaczewska M, et al.: Pharmacology of the urotensin II receptor antagonist ACT-058362: first demonstration of a pathophysiological role of the urotensin system. J Pharmacol Exp Ther 2004, 311:204\u2013212.","journal-title":"J Pharmacol Exp Ther"},{"key":"10_CR48","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.clpt.2006.05.013","volume":"80","author":"P.N. Sidharta","year":"2006","unstructured":"Sidharta PN, Wagner FD, Bohnemeier H, et al.: Pharmacodynamics and pharmacokinetics of the urotensin II receptor antagonist palosuran in macroalbuminuric, diabetic patients. Clin Pharmacol Ther 2006, 80:246\u2013256.","journal-title":"Clin Pharmacol Ther"},{"key":"10_CR49","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.yjmcc.2006.05.008","volume":"41","author":"N. Bousette","year":"2006","unstructured":"Bousette N, Hu F, Ohlstein EH, et al.: Urotensin-II blockade with SB-611812 attenuates cardiac dysfunction in a rat model of coronary artery ligation. J Mol Cell Cardiol 2006, 41:285\u2013295.","journal-title":"J Mol Cell Cardiol"},{"key":"10_CR50","unstructured":"Palosuran in Clinical Development. Available at: http:\/\/www.actelion.com\/uninet\/www\/www_main_p.nsf\/Content\/Other+Projects+in+Clinical+Development."}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-007-0010-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11906-007-0010-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-007-0010-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-007-0010-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T20:09:04Z","timestamp":1652904544000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11906-007-0010-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,3]]}},"alternative-id":["10"],"URL":"https:\/\/doi.org\/10.1007\/s11906-007-0010-x","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,3]]},"assertion":[{"value":"26 April 2007","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}